Ambroxol, 7.5 mg/ml 100 ml

Ambroxol has secretomotor, secretolytic and expectorant action: it stimulates serous glandular cells of bronchial mucosa, increases the content of mucous secretion and release of surfactant (surfactant) in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and increasing the release of lysosomes from the clara cells it reduces the viscosity of sputum.

Increases motor activity of the cilia of the atopic epithelium. Increases motor activity of the atopic epithelium, increases mucociliary transport, facilitates expulsion of sputum from the airways.

Indications

Diseases of the respiratory tract, accompanied by the release of viscous sputum and difficulty in sputum discharge: acute and chronic bronchitis; pneumonia; bronchial asthma; bronchiectasis; COPD

Pharmacological effect

Ambroxol has a secretomotor, secretolytic and expectorant effect: it stimulates the serous cells of the glands of the bronchial mucosa, increases the content of mucous secretion and the release of surfactant in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and enhancing the release of lysosomes from Clara cells, it reduces the viscosity of sputum.

Increases the motor activity of the cilia of the ciliated epithelium. Increases the motor activity of the ciliated epithelium, increases mucociliary transport, and facilitates the removal of mucus from the respiratory tract.

Special instructions

Ambroxol should not be taken simultaneously with antitussive drugs that can inhibit the cough reflex, for example, codeine, because this may make it difficult to remove liquefied mucus from the bronchi.

Ambroxol should be used with caution in patients with a weakened cough reflex or impaired mucociliary transport due to the possibility of sputum accumulation.

Patients taking ambroxol are not recommended to perform breathing exercises due to difficulty in sputum discharge. In critically ill patients, aspiration of liquefied sputum should be performed.

You should not take ambroxol immediately before bed.

In patients with bronchial asthma, ambroxol may increase cough.

In patients with severe skin lesions – Stevens-Johnson syndrome or toxic epidermal necrolysis – a flu-like condition may be observed in the early phase: fever, body pain, rhinitis, cough, pharyngitis. During symptomatic therapy, it is possible to erroneously prescribe mucolytic drugs such as ambroxol hydrochloride.

Active ingredient

Ambroxol

Composition

1 ml of solution contains:
Active substance: ambroxol hydrochloride – 7,500 mg
Excipients:
benzalkonium chloride – 0.225 mg,
sodium chloride – 6.220 mg,
citric acid – 2,000 mg,
sodium hydrogen phosphate dihydrate – 4.350 mg,
water – 989.705 mg

Contraindications

Hypersensitivity to ambroxol or auxiliary components of the drugs; I trimester of pregnancy; lactation period (breastfeeding); congenital fructose intolerance (for dosage forms containing fructose); children under 6 years of age (for tablets); children under 12 years of age (for extended-release capsules).

With caution: impaired bronchial motility and increased mucus secretion (for example, with rare immotile cilia syndrome); renal failure and/or severe liver failure; peptic ulcer of the stomach and duodenum (including a history); II and III trimesters of pregnancy; children under 2 years of age (oral solution; only as prescribed by a doctor).

Side Effects

Allergic reactions: rarely – skin rash, urticaria, exanthema, facial swelling, shortness of breath, itching, fever; frequency unknown – anaphylactic reactions, including anaphylactic shock, angioedema, itching, allergic contact dermatitis.

From the digestive system: often – nausea; uncommon – vomiting, diarrhea, dyspepsia, abdominal pain.

From the nervous system: often – dysgeusia.

From the skin and subcutaneous tissues: very rarely – toxic epidermal necrolysis (Lyell’s syndrome), Stevens-Johnson syndrome; frequency unknown – acute generalized eczematous pustulosis.

From the respiratory system: often – decreased sensitivity in the mouth or pharynx; rarely – dryness of the mucous membrane of the respiratory tract, rhinorrhea; in isolated cases – dryness of the pharyngeal mucosa.

Interaction

Antitussives (for example, codeine) – due to the suppression of the cough reflex, accumulation of sputum in the lumen of the respiratory tract is possible, making it difficult to remove it (simultaneous use is not recommended).

Amoxicillin, doxycycline, cefuroxime, erythromycin – increased penetration of antibiotics into bronchial secretions.

Overdose

Symptoms: heartburn, dyspepsia, diarrhea, nausea, vomiting, pain in the upper abdomen. There are reports of short-term anxiety. In case of severe overdose, a significant decrease in blood pressure is possible.

Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug; intake of fat-containing foods, symptomatic therapy.

Recommendations for use

The drug is taken orally after meals, adding to water, tea, milk or fruit juice.

Adults and children over 12 years of age: the first 2-3 days, 4 ml 3 times a day (which corresponds to 90 mg of ambroxol per day), then 4 ml 2 times a day (which corresponds to 60 mg of ambroxol per day);

Children from 6 to 12 years old: 2 ml 2-3 times a day (which corresponds to 30 or 45 mg of ambroxol per day);

Children from 2 to 6 years old: 1 ml 3 times a day (which corresponds to 22.5 mg of ambroxol per day);

Children under 2 years of age: 1 ml 2 times a day (which corresponds to 15 mg of ambroxol per day).

For children under 2 years of age, the drug is prescribed only under the supervision of a physician.

Maximum daily dose when taken orally: for adults – 90 mg, for children 6-12 years old – 45 mg, for children 2-6 years old – 22.5 mg, for children under 2 years old – 15 mg.

Storage conditions

In a place protected from light at a temperature
no higher than 25 °C.
Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Ozon, Russia